Loading patent…
AssigneeAgency for Science, Technology and Research
InventorLance D. Miller
Estimating the term…
The present invention relates to methods of controlling tumorigenesis, including preventing, inhibiting, arresting or reversing tumorigenesis. The present invention also provides methods of treatment, prevention and diagnosis of neoblastoma, including cancer, such as metastatic cancer. In one method one or more cells having a predisposition to turn tumorigenic are identifyied. In the one or more cells an altered amount, an altered subcellular localisation or an altered activity of a Rab binding protein is detected. In a method of diagnosing the risk of developing a neoplasmt at least one of the expression level, the activity level and the subcellular localisation of a Rab binding protein is determined. In an in-vitro method of identifying a compound capable of forming a complex with a Rab binding protein the components that form the respective complex are contacted with each other. In a method of determining whether a neoplasm is sensitive to an alteration of intracellular calcium levels, at least one of the expression and the activity of a Rab binding protein is determined. An altered expression or an altered activity of the Rab binding protein is an indication that the neoplasm is sensitive to an alteration of intracellular calcium levels.
A method of preventing, inhibiting, arresting or reversing tumorigenesis in a cell, the method comprising modulating the expression or the activity of a Rab binding protein, wherein the Rab binding protein is a Rab11FIP protein (Rab11 family-interacting protein).
2-68. (canceled)
A method of identifying a cell having a predisposition to turn tumorigenic, the method comprising detecting in the cell an altered expression, an altered subcellular localisation or an altered activity of a Rab binding protein, wherein the Rab binding protein is a Rab11FIP protein.
A method of diagnosing the risk of developing a neoplasm in a subject, the method comprising determining at least one of the expression level, the activity level and the subcellular localisation of a Rab binding protein, wherein the Rab binding protein is a Rab11FIP protein.
An in-vitro method of identifying a compound capable of forming a complex with a Rab binding protein, wherein the Rab binding protein is a Rab11FIP protein, the method comprising contacting the components that form said complex with each other.
A method for identifying a compound capable of modulating the activity of a Rab binding protein in vivo, wherein the Rab binding protein is a Rab11FIP protein, the method comprising:
A method for identifying a compound capable of modulating the expression of a Rab binding protein in vivo, wherein the Rab binding protein is a Rab11FIP protein, the method comprising:
A method of identifying a compound capable of modulating the expression or the activity of a Rab binding protein, wherein the Rab binding protein is a Rab11FIP protein, the method comprising:
A method of identifying a compound capable of modulating the expression or the activity of a Rab binding protein, wherein the Rab binding protein is a Rab11FIP protein, the method comprising:
A method of determining whether a neoplasm is sensitive to an alteration of intracellular calcium levels, the method comprising determining at least one of the expression and the activity of a Rab binding protein, wherein the Rab binding protein is a Rab11FIP protein, wherein an altered expression or an altered activity of the Rab binding protein is an indication that the neoplasm is sensitive to an alteration of intracellular calcium levels.
Dependencies are inferred from the claim text.